Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma

Cancer. 1994 Apr 1;73(7):1870-7. doi: 10.1002/1097-0142(19940401)73:7<1870::aid-cncr2820730716>3.0.co;2-3.

Abstract

Background: The prognostic significance of flow cytometric DNA ploidy and S-phase fraction (SPF) in ovarian cancer has been controversial. In the current study, the authors analyzed tumor heterogeneity in respect to DNA index DI and SPF.

Methods: Flow cytometric variation in DI and SPF among representative fresh tumor material from the primary tumor, metastasis, and malignant effusions from the same patient was analyzed.

Results: One hundred thirty-two samples from 47 patients were analyzed, and 119 samples from 42 patients were evaluable. Stable DI between different samples was found in 34 patients, whereas heterogeneity was found in 8 patients (19%). The metastases showed stable DNA content. The malignant effusion samples often lacked tumor cells. The representative ones were often DNA diploid. In 21% of the aneuploid samples, the SPF could not be analyzed. In 38% of the aneuploid samples, the stem line constituted less than 15% of measured nuclei. In these samples, a negative correlation between SPF and percentage of aneuploid cells was found, making SPF unreliable. Correct SPF measurement was thus possible in only 41% of the aneuploid samples, and in these tumors, SPF values varied considerably among different samples from the same patient, illustrated by a median SPF difference of 11% (range, 0-28%).

Conclusions: Tumor DI heterogeneity existed in 19% of tumors. SPF depended on the amount of aneuploid cells in case of small stem lines and varied considerably, making its use as a prognostic factor doubtful. To ensure that all tumor stem lines are represented, at least two biopsy specimens from any solid tumor should be analyzed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aneuploidy
  • Carcinoma / genetics*
  • Carcinoma / pathology*
  • Carcinoma / secondary
  • DNA / genetics*
  • Diploidy
  • Female
  • Flow Cytometry
  • Follow-Up Studies
  • Humans
  • Middle Aged
  • Neoplasm Staging
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / pathology*
  • Pleural Effusion, Malignant / genetics
  • Pleural Effusion, Malignant / pathology
  • Ploidies*
  • Prognosis
  • Prospective Studies
  • S Phase* / genetics
  • Survival Rate

Substances

  • DNA